Skip to content
Open access

Empagliflozin Attenuates Left Ventricular Remodeling in Diabetic Rats: Involvement of SIRT1/PINK1 Signaling

Oct 2026 · Cardiology Discovery · 0 citations · 38 references

TL;DR

Empagliflozin attenuated left ventricular remodeling and improved mitochondrial function in diabetic rats, with SIRT1/PINK1 signaling potentially contributing to these beneficial effects.

Abstract

To explore the role of sirtuin 1 (SIRT1)/PTEN-induced kinase 1 (PINK1) signaling in diabetic ventricular remodeling and investigate the effects of empagliflozin on this process. Diabetes mellitus was induced in male Sprague-Dawley rats using a high-fat diet combined with low-dose streptozotocin. Successfully induced diabetic rats were enrolled in batches and randomly assigned to the diabetes mellitus, low-dose empagliflozin (10 mg/kg daily), or high-dose empagliflozin (30 mg/kg daily) group. The first batch included 6 rats per group, and additional rats were enrolled in the second batch to reach a final sample size of 8 rats per group. Age-matched non-diabetic rats served as controls ( n = 8). After 8 weeks of treatment, cardiac structure and function were evaluated by echocardiography and invasive hemodynamic measurements, and myocardial hypertrophy and fibrosis were assessed histologically. Mitochondrial respiratory function and membrane potential were evaluated by respiratory control ratio and JC-1 fluorescence, respectively. SIRT1, nuclear respiratory factor 1 (NRF-1), and PINK1 protein expression levels were assessed by Western blotting. In H9c2 cells exposed to high glucose, the involvement of SIRT1 signaling was further investigated using the SIRT1 inhibitor EX527 and SIRT1-specific small interfering RNA. Compared with control rats, diabetic rats exhibited greater left atrial diameter, interventricular septal thickness, left ventricular posterior wall thickness, cardiomyocyte cross-sectional area, and myocardial fibrosis, together with impaired diastolic and hemodynamic function (all P < 0.05). Empagliflozin treatment attenuated these structural and functional abnormalities, although the significant effects varied according to dose. The mitochondrial respiratory control ratio and JC-1 red/green fluorescence ratio were significantly lower in diabetic rats than in controls (both P < 0.001) and were significantly higher following empagliflozin treatment (all P < 0.05). SIRT1, NRF-1, and PINK1 protein expression levels were significantly lower in diabetic myocardium and high-glucose-exposed H9c2 cells than in corresponding controls (all P < 0.05). In H9c2 cells, SIRT1 inhibition with EX527 was associated with lower SIRT1, NRF-1, and PINK1 protein expression following EMPA treatment (all P < 0.05). Empagliflozin attenuated left ventricular remodeling and improved mitochondrial function in diabetic rats, with SIRT1/PINK1 signaling potentially contributing to these beneficial effects.

Read PDF

Similar papers

Nov 2026

Abstract 9996: Differential Effects of Ovarian Hormone Deprivation and Empagliflozin on Cardiac Remodeling in Type 2 Diabetic Mice

Background: Type 2 diabetes (T2D) contributes to adverse cardiac remodeling, while female sex hormone deprivation further increases susceptibility to metabolic disorders. Although randomized controlled trials have demonstrated that sodium-glucose cotransporter-2 inhibitors (SGLT2i) can reduce left ventricular mass i...

K. Piyanirun, Weerapat Kositanurit, D. Werawatganon et al. · 0 citations
Open access Oct 2026

Empagliflozin promotes reverse remodeling via cardiometabolic reprogramming in established pressure-overload left ventricular hypertrophy

Left ventricular hypertrophy (LVH) due to chronic pressure overload is a major precursor of heart failure (HF) and is characterized by metabolic inflexibility and mitochondrial dysfunction. Sodium–glucose cotransporter-2 inhibitors (SGLT2i) improve HF outcomes; however, their myocardial mechanisms in LVH remain i...

M. Ernst, A. I. Goncalves, C. Dostal et al. · 0 citations
Open access Oct 2026

Vildagliptin attenuates thioacetamide-induced hepatic fibrosis in rats: associations with AMPK/SIRT1/Nrf2 and STAT3/TGF-β1 signaling

Abstract Objective Liver fibrosis is a progressive consequence of chronic injury with limited treatment options. Vildagliptin (Vilda), a dipeptidyl peptidase-4 inhibitor, possesses antioxidant and anti-inflammatory properties, but its effects on thioacetamide (TAA)-induced liver fibrosis are not fully characterized. Th...

Mohannad A. Almikhlafi, May A. Alsayb, Sara A. Almadani et al. · 0 citations
Open access Oct 2026

Sotagliflozin corrects myocardial phenotype, mitochondrial gene expression and oxidative stress in mice with hypertrophic cardiomyopathy

Background Hypertrophic cardiomyopathy (HCM) is associated with mitochondrial dysfunction and oxidative stress. Objective Our goal was to determine the effects of the dual Sodium-Glucose-Linked-Transporter (SGLT) 1 and 2 inhibitor sotagliflozin (SOTA) on myocardial remodeling, diastolic function, mitochondrial gene exp...

Fu-Zhong Qin, D. Pimentel, T. Baka et al. · 0 citations
Open access Jan 2026

Naringenin Attenuates Diabetic Cardiac Injury via SIRT1 Activation in Streptozotocin‐Induced Rats

Objective Diabetic cardiomyopathy (DCM) lacks targeted therapies. This study investigated naringenin (NAR), a citrus flavonoid, in a streptozotocin (STZ)‐induced diabetic rat model with cardiac complications, focusing on SIRT1‐mediated mechanisms. Methods Rats (n = 8/group) included control, NAR, DCM, DCM + NAR, and DC...

Bao-Lan Wang, Dan-Dan Zhang, Fu-Dan Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.